M&A - GoINPHARMA
Thursday, 13 December 2018 - 23:52

M&A

Bausch Health (former Valeant) invests $200m in buying Synergy Pharma

Bausch Health–former Valeant–has announced it has acquired Synergy Pharma for $200m, after the company had already gone into voluntary liquidation and started filing for bankruptcy. Synergy’s key asset is surely Trulance, a therapy approved by FDA and Chinese authorities for…

Japan’s Taisho submits its offer to buy BMS’ Upsa (€1bn)

Italian daily Il Messaggero some days ago reported 4 bids for France-based Upsa, put up for sale by US-based group Bristol-Myers Squibb. The article added that pharmaceutical group Angelini made a more profitable bid than private equities PAI Partners and…

GSK acquires Tesaro for $5.1bn

After having announced job cuts, reorganizing plans and pipeline rationalization for countless times, GlaxoSmithKline’s CEO Emma Walmsley today announced, as trading started in Europe, her first acquisition. Indeed, GSK informed it has acquired US-based biotech Tesaro for $5.1bn in cash….

Takeda ready to dismiss assets for a total $10bn

Japan economic and financial daily Nihon KeizaiShimbun yesterday reported that Takeda Pharmaceutical is about to divest assets for $10bn in order to offset the debt–which has reached $48bn now–built up by acquiring Shire for $62bn. The newspaper also reports a…

Angelini most likely buyer of Upsa (Bristol-Myers Squibb)

Italian daily Il Messaggero today has reported that Angelini is the most likely candidate to acquire its French competitor Upsa, belonging to US-based Bristol-Myers Squibb. The article mentions as sources the banks hired to manage the transaction. Four companies have…

Gilead can now attempt at takeover of Galapagos

The Dutch economic and financial daily Het Financieele Dagblad today has reviewed the press release issued by Belgian-Dutch biotech company Galapagos to announce that Van Herk Investments’ stake in the company has decreased to 9.91% due to dilution. As a…

Unilever ready to acquire Horlick from GSK for about $4bn

Britain-based Unilever and GlaxoSmithKline are reportedly in exclusive talks now over a sale of India-based Holrlick–a subsidiary of GlaxoSmithKline’s–for an approximate $4bn. An acquisition of Horlick is reportedly consistent with Unilever’s latest strategic moves; moreover, it would increase its presence…

Private equity Ardian gains control of Neopharmed Gentili

Italian economic-financial daily Il Sole 24 Ore has reported today that Mediulanum Farmaceutici has sold its subsidiary Neopharmed Gentili to private equity Ardian. Neopharmed in 2017 generated sales of €192m. (Source Il Sole24Ore)

Xio might sell Lumenis to CVC for 1 billion dollars

Private equity XIO is seeking to sell Lumenis, Israel-based medical devices producer for plastic surgery. Xio acquired Lumenis in 2015 for $520m and its value has almost doubled to $1bn three years after the acquisition. The Israeli company boasts a…

Private equities step forward to acquire Nestlé Skin Health

The Sunday Times today has reported that Nestlé’s Skin Health division has attracted interest from private equity firms CVC Capital Partners, Carlyle Group and TPG. Nestlé’s asset marketing skin health products has been put up for sale due to pressure…

Behind the scenes of Bayer-Monsanto deal

The Wall Street Journal today has published a long article rehearsing the history of Monsanto acquisition by Germany-based Bayer. The deal is the result of new CEO Werner Baumann’s perseverance: for years, he had been seeking to convince the top…

European authorities approve Takeda’s GBP46bn purchase of Shire

European antitrust authorities today have approved Takeda Pharmaceutical’s GBP46bn acquisition of Shire, on condition that Takeda sells its SHP647 Crohn’s disease therapy, currently undergoing a Phase III clinical trial. The acquisition has already been approved by the Chinese, Japanese and…

Boston Scientific announces acquisition of BTG for GBP3.3bn

US-based medical devices producer Boston Scientific has acquired its UK-based competitor BTG for GBP3.3bn. Boston Scientific has valued BTG 840p per share, which means a premium 36% over Monday’s closing price. The move will strengthen Boston Scientific’s position in the…

Renewed talk about Gilead seeking to acquire Tesaro ($2bn)

Bloomberg has reported that Tesaro is seeking a sale, which was enough for its shares to be up over 30% as trading closed last Friday. According to the report, some potential acquirers have already stepped up, and the company’s management…

Time for radical change at Novartis

Swiss daily newspaper Tagesanzeiger reported that Novartis – with a CHF223bn market capitalization – aims at splitting Sandoz division from the rest of the company, thus making it completely independent. New 42-year-old CEO Vas Narasimhan reportedly said so while dining…

AstraZeneca sells Synagis for 1.5 billion dollars

AstraZeneca’s shares rose over 1% today (London) as the group led by Pascal Soriot announced that it has sold to Swedish Orphan Biovitrum AB (SOBI) the rights to market its therapy for respiratory diseases Synagis in the US . The…

Angelini and Stada fighting for Bristol-Myers Squibb’s Upsa (€1bn)

German economic-financial daily Handelsblatt yesterday reported that Germany-based generics producer Stada has been shortlisted to make final bids for France-based Upsa, owned by US-based multinational Bristol-Myers Squibb. In addition to Stada, Italy-based Angelini and private equities CVC Capital Partners e…

Pharming Group vulnerable to takeover by other pharmaceutical groups

De Telegraaf yesterday evening reported that Netherlands-based Pharming Group is already targeted by large groups seeking acquisitions. The information directly comes from investment bank Stifel. Prospective buyers include Amryt, Consort Medical, Indivior and Valneva. The Dutch group’s main asset is…

Takeda considering sale of OTC business in Europe ($11bn)

Takeda Pharmaceuticals is reportedly assessing, jointly with analysts from investment bank JP Morgan, a sale of OTC business in Europe. Selling the asset is likely to offset the debt built up by acquiring Shire for $62bn, indeed it is likely…

AbbVie acquires Galapagos’ cystic fibrosis portfolio for $245m

AbbVie has surprised investors by announcing it has acquired the cystic fibrosis portfolio from Belgium-based Galapagos. The deal includes an upfront $45m payment, plus additional  payments based on successful completion of precise milestones, up to $200m. AbbVie’s move has surprised…

AstraZeneca invests almost 1 billion in partnership with Innate Pharma

AstraZeneca has announced it has expanded its scientific cooperation agreement with biotech Innate Pharma, signed in 2015. By expanding the agreement, the British-Swedish group seeks to strengthen its portfolio of immunotherapies for cancer. Specifically, the deal provides AstraZeneca with a…

Johnson & Johnson acquires Japan-based Ci:z Holdings for $2.05bn

Johnson & Johnson has informed markets that it plans to acquire 80% of Japan-based Ci:z Holdings for ¥230bn ($2.05bn), of which it already owns 20%. Johnson and Johnson’s move strengthens the US group’s presence in the rich Japanese market of…

Amgen becomes shareholder of Oxford Nanopore (DNA sequencers)

US-based biotech group Amgen has announced a GBP50m equity investment in Britain-based Oxford Nanopore, manufacturing DNA sequencers. Amgen’s move aligns with its focus on using human genetics to research for new therapies addressing some major diseases. Indeed, Amgen already has…

M&A splash for Novartis: announced acquisition of Endocyte for $2.1bn

Novartis today announced, before trading opened, that it has acquired the US-based biotech Endocyte for $2.1bn. Novartis has valued the company at $24 per share, that is a 54% premium over yesterday’s closing price. Endocyte is focusing on Precision Medicine,…

How AbbVie protects Humira from biosimilars

Sandoz-Novartis some days ago announced it had reached an agreement with US-based AbbVie. As a result, the launch of Hyrimoz (adalimumab), the biosimilar to blockbuster Humira (adalimumab) was postponed to September 2023. Additionally, the agreement will allow Sandoz to start…

Allergan sells Rhofade for €65m

US-based Aclaris Therapeutics (Pennsylvania) has acquired global rights to Allergan’s Rhofade. The drug is a cutaneous therapy for the treatment of cutaneous facial erythema, which in 2011 was  included into Allergan’s portfolio following the acquisition of Vicept Therapeutics. (Source: Aclaris)

Bayer considering sale of Animal Health business (€6-7bn)

Werner Baumann, CEO of Germany-based group Bayer, has told in an interview that his company’s management is assessing a sale of the Animal Health division. The segment last year delivered €1.6bn, with a 24% EBITDA. The sale might fetch Bayer…